SCLXライブシグナル | Getagraph.comで利益を最大化

Live Chart Being Loaded With Signals

Commentary (11 6月 2024 @ 23:34):

Scilex Holding Company, a biopharmaceutical company, focuses on developing and commercializing non-opioid management products for the treatment of acute and chronic pain...

Stats
本日の出来高	42 052
平均出来高	886 939
時価総額	210.18M
EPS	$-0.240 ( Q1 \| 2024-05-13 )
次の収益日	( $-0.180 ) 2024-08-09
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-0.890 (Sector) 42.63 (Industry) 61.14
ATR14	$0.00700 (0.60%)

CRXT -31.16%

MIRA 2.61%

SCLX 3.57%

SCLXW 0.00%

Insider Trading

Date	Person	Action	Amount	type
2024-05-17	Ji Henry	Buy	50 000	Common Stock
2024-05-17	Chun Jay	Buy	57 500	Common Stock
2024-05-17	Shah Jaisim	Buy	56 939	Common Stock
2024-05-16	Shah Jaisim	Buy	83 061	Common Stock
2024-05-17	Ma Stephen Hoi	Buy	14 140	Common Stock

INSIDER POWER
-85.52
Last 53 transactions
Buy: 18 104 987 \| Sell: 160 710 385

ボリューム相関

長: -0.30 (neutral)

短: 0.00 (neutral)

Signal:(56.025) Neutral

Scilex Holding Company 相関

10 最も正の相関

10 最も負の相関

知っていましたか？

相関は、2つの変数間の関係を説明する統計的指標です。相関係数は-1から1までの値を取り、-1は完全な負の相関（1つの変数が増加すると、もう一方は減少する）、1は完全な正の相関（1つの変数が増加すると、もう一方も増加する）、0は相関がないことを示します（変数間に関係がない）。

相関は、株式だけでなく、どの2つの変数間の関係にも適用できます。これは、金融、経済学、心理学などの分野で一般的に使用されています。

Scilex Holding Company 相関 - 通貨/商品

-0.75
( moderate negative )

-0.58
( weak negative )

0.00
( neutral )

0.79
( moderate )

Scilex Holding Company 財務諸表

Annual	2023
収益:	$46.74M
総利益:	$26.92M (57.58 %)
EPS:	$-0.880

FY	2023
収益:	$46.74M
総利益:	$26.92M (57.58 %)
EPS:	$-0.880

FY	2022
収益:	$38.03M
総利益:	$27.24M (71.61 %)
EPS:	$-0.170

Financial Reports:

No articles found.

Scilex Holding Company Options Data

Calls

Contract Name	Last Trade Date (EDT)	Strike	Last Price	Bid	Ask	Change	% Change	Volume	Open Interest	Implied Volatility	Strike Date
No data available

Puts

Contract Name	Last Trade Date (EDT)	Strike	Last Price	Bid	Ask	Change	% Change	Volume	Open Interest	Implied Volatility	Strike Date
No data available

Scilex Holding Company

Scilex Holding Company, a biopharmaceutical company, focuses on developing and commercializing non-opioid management products for the treatment of acute and chronic pain. Its commercial product is ZTlido 1.8%, a prescription lidocaine topical product for the relief of neuropathic pain related with post-herpetic neuralgia, which is a form of post-shingles nerve pain. It also offers SP-102, a viscous gel formulation of corticosteroid for epidural injections that is in a Phase III clinical trial to treat lumbosacral radicular pain; SP-103, which is in Phase II clinical trail for the treatment of low back pain; and SP-104, a novel low-dose delayed-release naltrexone hydrochloride formulation that has completed Phase I clinical trial for the treatment of fibromyalgia. The company is headquartered in Palo Alto, California. Scilex Holding Company is a subsidiary of Sorrento Therapeutics, Inc.